Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)

Journal of Pain and Symptom Management

Volumn 43, Issue 2, 2012, Pages 205-217

  Romanus, Dorothy ^a   Kindler, Hedy L ^b   Archer, Laura ^c   Basch, Ethan ^d   Niedzwiecki, Donna ^c   Weeks, Jane ^e   Schrag, Deborah ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c CALGB Statistical Center   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Advanced pancreas cancer; gemcitabine; quality of life

Indexed keywords

BEVACIZUMAB; GEMCITABINE; PLACEBO;

ADVANCED CANCER; ADVANCED PANCREAS CANCER; AGED; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DEPRESSION; DETERIORATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PAIN; PAIN ASSESSMENT; PANCREAS CANCER; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84855888029     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2011.09.001     Document Type: Article

References (23)

1. C. Louvet, R. Labianca, and P. Hammel Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
2. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966 (Pubitemid 46972777)
3. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with APC: a randomized trial J Clin Oncol 15 1997 2403 2413 (Pubitemid 27251144)
4. M. Reni, E. Bonetto, and S. Cordio Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial Pancreatology 6 2006 454 463 (Pubitemid 44624279)
5. K. Hoffman, and B. Glimelius Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer Acta Oncol 37 1998 651 659 (Pubitemid 29066816)
6. S. Cascinu, R. Labianca, and B. Daniele Survival and quality of life in gastrointestinal tumors: two different end points? Ann Oncol 12 Suppl 3 2001 S31 S36
7. S.R. Bramhall, J. Schulz, and J. Nemunaitis A double-blind placebo-controlled randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161 167
8. V. Heinemann, D. Quietzsch, and F. Gieseler A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma Proc Am Soc Clin Oncol 2003 22 Abstract 1003
9. H. Oettle, D. Richards, and R.K. Ramanathan A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 2005 1639 1645 (Pubitemid 41510138)
10. M.J. Moore, J. Hamm, and J. Dancey Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296 3302 (Pubitemid 46606263)
11. E. Van Cutsem, H. van de Velde, and P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438 (Pubitemid 41103625)
12. H.L. Kindler, D. Niedzwiecki, and D. Hollis A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 25 18S 2007 4508
13. EuroQol Group. EQ-5D. Available from http://www.euroqol.org. Accessed April 25, 2008.
14. D. Osoba, G. Rogrigues, and J. Myles Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144 (Pubitemid 28041591)
15. P. Kind The EuroQol instrument: an index of health-related quality of life B. Spilker, Quality of life and pharmacoeconomics in clinical trials 2nd ed. 1996 Lippincott-Raven Press Philadelphia, PA 191 201
16. J.W. Shaw, J.A. Johnson, and S.J. Coons US valuation of the EQ-5D health states - development and testing of the D1 valuation model Med Care 43 2005 203 220 (Pubitemid 40353904)
17. Q. Xia, S. Hwang, and V.T. Chang Validity, reliability and responsiveness of Euroqol (EQ5D) in patients (pts) receiving palliative care (PC) Proc Am Soc Clin Oncol 23 16S 2005 8082
18. M.R. Gold, J.E. Siegel, and L.B. Russell Cost-effectiveness in health and medicine 1996 Oxford University Press New York
19. E. Lydick, and R.S. Epstein Interpretation of quality of life changes Qual Life Res 2 1993 221 226 (Pubitemid 23203446)
20. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables J Clin Oncol 26 2008 3913 3915
21. G.W. Snedecor, and W.G. Cochrane Statistical methods 7th ed. 1980 Iowa State University Ames, IA 192
22. S.M. Park, M.H. Park, and J.H. Won EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units Support Care Cancer 14 2006 329 333
23. P.F. Krabbe, L. Peerenboom, B.S. Langenhoff, and T.J. Ruers Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30 Qual Life Res 13 2004 1247 1253 (Pubitemid 39149608)